As at the Latest Practicable Date, ethical committee approval had been obtained from 14 medical institutions for the clinical trial for EAL®. These institutions are located in Beijing, Tianjin, Henan ,Hebei , and are set out as follows:
·Chinese PLA General Hospital
·Peking University People’s Hospital
·Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
·Cancer Hospital, Chinese Academy of Medical Sciences
·Beijing Youan Hospital, Capital Medical University
·Beijing Cancer Hospital
·The Sixth Medical Centre of Chinese PLA General Hospital
·The Fifth Medical Centre of Chinese PLA General Hospital
·Tianjin Medical University Cancer Institute & Hospital
·Beijing Tiantan Hospital, Capital Medical University
·Henan Cancer Hospital
·The First Hospital of Hebei Medical University
·The Fourth Hospital of Hebei Medical University
·The First Affiliated Hospital of Zhengzhou University
If you meet the following criteria:
Understand and voluntarily sign an informed consent form;
Age 18 to 75 years old, men and women are not limited;
Primary hepatocellular carcinoma patients;
According to the National Health and Family Planning Commission of the People's Republic of China primary liver cancer diagnosis and treatment norms (2017 version) of the clinical phase of liver cancer, Phase III.a patients;
Child-Pugh score of 7 points;
Undergo a curly excisectomy of primary liver cancer (including open abdominal surgery or laparoscopic surgery);
Then you may meet the inclusion criteria for the study.